| Literature DB >> 31569778 |
Jing Li1, Xianqing He2, Yuanyuan Deng3, Chenxi Yang4.
Abstract
Extracellular vesicles (EVs) are lipid bilayer enclosed particles which present in almost all types of biofluids and contain specific proteins, lipids, and RNA. Increasing evidence has demonstrated the tremendous clinical potential of EVs as diagnostic and therapeutic tools, especially in biofluids, since they can be detected without invasive surgery. With the advanced mass spectrometry (MS), it is possible to decipher the protein content of EVs under different physiological and pathological conditions. Therefore, MS-based EV proteomic studies have grown rapidly in the past decade for biomarker discovery. This review focuses on the studies that isolate EVs from different biofluids and contain MS-based proteomic analysis. Literature published in the past decade (2009.1-2019.7) were selected and summarized with emphasis on isolation methods of EVs and MS analysis strategies, with the aim to give an overview of MS-based EV proteomic studies and provide a reference for future research.Entities:
Keywords: biofluid; extracellular vesicles; isolation methods; mass spectrometry; proteomics
Mesh:
Substances:
Year: 2019 PMID: 31569778 PMCID: PMC6803898 DOI: 10.3390/molecules24193516
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Publication trends on extracellular vesicle studies in the past decade (2009.1 to 2019.7). Publications were selected by searching the keyword “extracellular vesicle” in the Web of Science from the year of 2009.1 to 2019.7. x axis: year; y axis: number of publications.
Figure 2A general workflow of mass spectrometry (MS)-based proteomic extracellular vesicle (EV) study. EVs are firstly isolated from various biofluids, and EV proteins are extracted by adding detergent or non-detergent containing lysis buffer. The extracted EV proteins can be separated by gel electrophoresis and digested in-gel before MS analysis. Alternatively, digestion can be performed after protein extraction, and the generated peptides are either fractionated by liquid chromatography (LC) before MS analysis or directly subjected to MS analysis. The MS analysis can be conducted in data-dependent acquisition (DDA) or data-independent acquisition (DIA) for discovery EV studies or multiple reaction monitoring (MRM) for target EV studies. Differential expressed EV proteins also can be revealed by quantitative MS analysis via label-free or labeled quantitative proteomics. CSF: cerebrospinal fluid; FASP: filter aided sample preparation; SCX: strong cation exchange chromatography; RP: reverse phase chromatography; TMT: tandem mass tag; iTRAQ: isobaric tag for relative and absolute quantitation.
Figure 3A basic differential ultracentrifugation (dUC) workflow for isolation of MVs and exosomes. Biofluids are diluted by phosphate-buffered saline (PBS) before centrifugation. Dead cells and cell debris are removed as pellets during the centrifugation at 1000–3000× g. Further centrifugation of supernatant at 10,000–20,000× g facilitates the isolation of MVs from exosomes. Finally, the recovery of exosomes is achieved by ultracentrifuging the 10,000–20,000× g-derived supernatant at 100,000–200,000× g.
Selected MS analysis for EVs obtained from centrifugation-based isolation.
| Isolation | Proteomic Sample Preparation | Mass Spectrometry | Sample Origin | Number of Proteins | Year | Study |
|---|---|---|---|---|---|---|
| 19,000× | 2D-LC/MS: SCX as 1st dimensional | LTQ ion trap | plasma | 1806 proteins | 2017 | [ |
| Sucrose cushion at 100,000× | 2D-LC/MS: C18-SCX stage-tip as 1st dimensional | Q-Exactive | serum | 702 proteins | 2017 | [ |
| 100,000× | iTRAQ | LTQ-Orbitrap Velos Elite | urine | 4710 proteins in total and 3528 proteins for quantification | 2017 | [ |
| Sucrose cushion at 100,000× | iTRAQ | Orbitrap Fusion Lumos | semen | 3699 proteins in total | 2018 | [ |
| 110,000× | FASP | Q Exactive | serum | 655 proteins | 2018 | [ |
| 10,000× | in-solution digestion | SWATH-MS | urine | Targeted data analysis for 888 proteins | 2018 | [ |
| Density ultracentrifugation at 270,000× | in-solution digestion | MSE | urine | 1877 proteins | 2011 | [ |
| 100,000× | in-solution digestion | L Q-Exactive Orbitrap | umbilical cord blood | 211 proteins | 2015 | [ |
| 200,000× | in-gel digestion | LTQ Orbitrap XL and LTQ Orbitrap Velos | urine | 1989 proteins in total | 2012 | [ |
| 100,000× | in-solution digestion | LTQ Orbitrap Velos | saliva | 381 proteins | 2015 | [ |
| 200,000× | iTRAQ | MALDI * tandem mass spectrometry | plasma | not report | 2010 | [ |
| Sucrose cushion at 192,000× | in-gel digestion | Q-Exactive | breast milk | 1963 proteins | 2016 | [ |
| 20,000× | in-solution digestion | Q-Exactive/Plus | plasma | 3294 proteins in 4 h LC/MS | 2015 | [ |
| 10,000 or 20,000× | SDS-PAGE FASP | Q-Exactive | saliva | 785 proteins for MVs; 910 proteins for exosomes | 2018 | [ |
| 20,000× | in-solution digestion | LTQ-Orbitrap Velos Pro | plasma | 9225 phosphopeptides in MVs; 1014 phosphopeptides in exosomes | 2017 | [ |
| 100,000× | in-gel digestion | LTQ-XL | CSF | 91 proteins identified from control466 proteins identified from disease | 2018 | [ |
* MALDI: Matrix-assisted laser desorption/ionization.
Selected comparative studies for EV isolation.
| Isolation Methods | Characterization Techniques | Samples | Study |
|---|---|---|---|
| dUC, SEC | NTA, Dissociation-enhanced lanthanide fluorescence immunoassay, WB, TEM | rat plasma, cell culture | [ |
| dUC, SEC | TEM, AFM, WB, MS | cell culture | [ |
| Affinity-based (exoEasy kit) and SEC (qEV) | WB, TEM, NTA, lipid quantification kit, RNA quality | plasma | [ |
| dUC and Commercial kit from Invitrogen, 101Bio, Wako and iZON | Dynamic Light Scattering, immunoblot analysis, qRT-PCR, MS, Cell Proliferation Assay | cell culture | [ |
| dUC, precipitation (ExoQuick, Total Exosome Isolation Reafent, Exo-PREP) and SEC (qEV) | TEM, NTA, WB | cell culture | [ |
| Lectin-based, Exoquick, Total exosome Isolation and in-house modified procedure | WB, Reverse transcriptase and qPCR, EM | urine | [ |
| dUC, precipitation (ExoQuick, Total exosome isolation, PEG, Exo-spin), filtration (ExoMir) | NTA, Flow cytometry, WB, PCR, | serum | [ |
| dUC, filtration (Stirred cell and Centricon), OptiPrep DG, ExoQuick, Exo-spin, SEC | Tunable resistive pulse sensing, EM, WB | cell culture and plasma | [ |
| SEC and Exo-Spin | NTA, Flow cytometry, MS | plasma | [ |
| dUC, anti-EpCAM, OptiPrep DG | MS, WB, TEM | plasma | [ |
| Nanomembrane ultrafiltration, dUC and dUC-SEC | MS, TEM, WB | urine | [ |
| dUC, anti-EpCAM, OptiPrep DG | TEM, CryoEM, MS | cell culture | [ |
| Sucrose DG and ExoQuick | TEM, NTA, WB | serum | [ |
* EM: electron microscopy; TEM: transmission electron microscopy; NTA: nanoparticle tracking analysis AFM: atomic force microscopy; WB: western blot.
Figure 4The schematic workflow for multi-enzyme digestion filter-aided sample preparation. This figure was adopted from Ref. [97].